Literature DB >> 9253967

Active prevention in diabetic eye disease. A 4-year follow-up.

J K Kristinsson1, H Hauksdóttir, E Stefánsson, F Jónasson, I Gíslason.   

Abstract

Ten years after the foundation of a national diabetic eye screening program in 1980, we have established a low prevalence of blindness and partial sight in type 1 and type 2 diabetics in Iceland. We ask whether the screening program is also associated with a low incidence of blindness in diabetics. We now report the results of a prospective study on the 4-year incidence of diabetic retinopathy and visual impairment in type 1 diabetics with age at onset less than 30 years. Out of 205 patients participating at baseline, 175 patients (85.4%) participated over the full 4-year period. Patients were examined annually and received laser treatment according to Diabetic- and Early Treatment Diabetic Retinopathy Study criteria. The 4-year incidence of any retinopathy was 38.1%, of proliferative retinopathy 6.6%, and of macular edema 3.4%. Out of 174 patients, 7.4% showed improvement in visual acuity of 2 Snellen lines while 2.5% experienced worsening of visual acuity of 2 Snellen lines during the 4-year period. No diabetic suffered more than 2 lines deterioration of vision and none became legally blind. The incidence of retinopathy in Icelandic type 1 diabetics participating in our annual eye screening program is low and the visual acuity stable. Our results suggest that visual impairment in diabetics can be prevented with active regular screening and standard laser therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9253967     DOI: 10.1111/j.1600-0420.1997.tb00766.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  8 in total

1.  Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.

Authors:  T Aspelund; O Thornórisdóttir; E Olafsdottir; A Gudmundsdottir; A B Einarsdóttir; J Mehlsen; S Einarsson; O Pálsson; G Einarsson; T Bek; E Stefánsson
Journal:  Diabetologia       Date:  2011-07-27       Impact factor: 10.122

2.  Biennial eye screening in patients with diabetes without retinopathy: 10-year experience.

Authors:  E Olafsdóttir; E Stefánsson
Journal:  Br J Ophthalmol       Date:  2007-07-12       Impact factor: 4.638

3.  A deep learning system for detecting diabetic retinopathy across the disease spectrum.

Authors:  Ling Dai; Liang Wu; Huating Li; Chun Cai; Qiang Wu; Hongyu Kong; Ruhan Liu; Xiangning Wang; Xuhong Hou; Yuexing Liu; Xiaoxue Long; Yang Wen; Lina Lu; Yaxin Shen; Yan Chen; Dinggang Shen; Xiaokang Yang; Haidong Zou; Bin Sheng; Weiping Jia
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

4.  Changes in detection of retinopathy in type 2 diabetes in the first 4 years of a population-based diabetic eye screening program: retrospective cohort study.

Authors:  Alice S Forster; Angus Forbes; Hiten Dodhia; Clare Connor; Alain Du Chemin; Sobha Sivaprasad; Samantha Mann; Martin C Gulliford
Journal:  Diabetes Care       Date:  2013-04-25       Impact factor: 19.112

Review 5.  The Diabetic Retinopathy Screening Workflow: Potential for Smartphone Imaging.

Authors:  Nigel M Bolster; Mario E Giardini; Andrew Bastawrous
Journal:  J Diabetes Sci Technol       Date:  2015-11-23

6.  Sensitivity and specificity of Norwegian optometrists' evaluation of diabetic retinopathy in single-field retinal images - a cross-sectional experimental study.

Authors:  Vibeke Sundling; Pål Gulbrandsen; Jørund Straand
Journal:  BMC Health Serv Res       Date:  2013-01-10       Impact factor: 2.655

7.  Care of vision and ocular health in diabetic members of a national diabetes organization: a cross-sectional study.

Authors:  Vibeke Sundling; Pål Gulbrandsen; Jak Jervell; Jørund Straand
Journal:  BMC Health Serv Res       Date:  2008-07-28       Impact factor: 2.655

8.  Irish National Diabetic RetinaScreen Programme: report on five rounds of retinopathy screening and screen-positive referrals. (INDEAR study report no. 1).

Authors:  Rajiv Pandey; Margaret M Morgan; Colette Murphy; Helen Kavanagh; Robert Acheson; Mark Cahill; Patricia McGettrick; Louise O'Toole; Fatima Hamroush; Therese Mooney; Helen Byrne; Patricia Fitzpatrick; David J Keegan
Journal:  Br J Ophthalmol       Date:  2020-12-17       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.